INDIA- Pharmaceutical company Bayer has introduced Finerenone under the brand name Kerendia, as a drug for the treatment of chronic kidney damage (CKD) brought on by Type 2 diabetes (T2D).
According to a press release from the firm, Finerenone is a first-in-class non-steroidal, selective mineralocorticoid receptor antagonist recommended for those with type 2 diabetes and chronic kidney disease.
Kerendia is the only drug of its kind that prevents mineralocorticoid receptor (MR) overactivation in the kidneys, heart, and blood vessels.
This is even while drugs for diabetes and high blood pressure may help one control their glucose and blood pressure.
The inflammation and scarring caused by MR overactivation may accelerate the onset of kidney disease. Additionally, this could worsen heart disease.
The progression of CKD in T2D is hypothesized to be slowed by blocking MRs. Therefore, there may be more to be done to delay the kidney damage caused by CKD, even if one is currently taking drugs for diabetes and high blood pressure.
Manoj Saxena, Managing Director, Bayer Zydus Pharma said that Finerenone, offers a new treatment approach for vulnerable patients to slow down the progression of chronic kidney disease and reduce the risk of kidney failure.
According to the authorization in India, Finerenone is recommended for adult patients with type 2 diabetes and chronic kidney disease (CKD).
Diabetes is the main contributor to chronic kidney disease and end-stage renal disease in India.
This is according to a new Indian Chronic Kidney Disease (ICKD) study. Diabetes patients are more than 40% more likely to have chronic renal disease.
According to several studies, there are 74 million diabetics in India, and that number is expected to rise to 93 million by 2030, making the disease an epidemic. After China, India has the second-highest global prevalence of diabetes.
The U.S. Food and Drug Administration authorized Finerenone in July of this year based on the findings of the clinical trials investigations (FDA).
Additionally, the European Commission gave marketing authorization for it in February of this year. The Indian health authorities then approved it in April of this year.
According to the authorization in India, Finerenone is recommended for adult patients with type 2 diabetes and chronic kidney disease (CKD).
This drug will help lower the risk of end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure (T2D).
Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE
